All News
Retrospective French case study showed PAH is rare but potentially severe complication of AOSD. In this trial of 13, it only affected women. Further studies needed! Abs 1100 #ACR21 #RheumNow @RheumNow https://t.co/6CufqRV0Qg https://t.co/h73mxsJswi
Dr. Rachel Tate uptoTate ( View Tweet)
Abst1094 #acr21 @RheumNow rheum pts and extremely ⬆️ESR: infection vs flare: Thrombocyte, MCV, albumin and total protein were significantly lower in infection group, however; neutrophil, MPV, CRP and ferritin were significantly lower in flare-up group https://t.co/C6MQo86Ljb
Olga Petryna DrPetryna ( View Tweet)
Urinary CD163: Potential Biomarker in LN
💠Correlated w/histological activity
💠⬆️in prolif LN
💠⬇️in responders
💠Clinical features + biomarkers may provide non-invasive method to dx and monitor response in LN
https://t.co/u910ehQH74
#ACR2021 Abst#1422 @RheumNow #ACRBest
Pedro Castillo _Castillo_Pedro ( View Tweet)
TCZ in COVID-19: studies that form the basis of the EUA, direct from the @US_FDA
(now can we have enough for our RA, GCA, and JIA pts still on it, please @genentech @Roche?)
#ACR21 FDA update @RheumNow https://t.co/ZQv9XtoRJZ
David Liew drdavidliew ( View Tweet)
“Geriatrics is a team sport!” – Dr. Buehring #ACR11 @rheumnow @UnaMakris #GeriRheum #aging https://t.co/ckAJsi696Y
TheDaoIndex KDAO2011 ( View Tweet)
#ACR21 #Abstr Are we close to not needing kidney biopsy to assess #lupus nephritis? A study showed Urinary CD163:
⬆️in proliferating LN
⬇️in responders with good AUC
Further works: ?marker for flare, how sensitive vs uPCR, different therapies
@RheumNow https://t.co/d0quh9wu5h https://t.co/zWm8SJvRXz
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Hip involvement/TJR assoc'd w/ MEFV+ vs HLA-B27+ in FMF/SpA pts vs SpA. FMF/SpA: more severe disease, worse outcomes, & destructive hip involvement vs SpA, particularly in pts with MEFV variants & M694V homozygosity. Abs 1108 #ACR21 #RheumNow @RheumNow https://t.co/hlnN26AYgE https://t.co/1jHeVxKs7O
Dr. Rachel Tate uptoTate ( View Tweet)
Very interesting talks by @UnaMakris and #DrBuhring on Multicomplexity in the Aging Patient with #RA
#ACR21 @RheumNow https://t.co/WA8YtEpKhk
Akhil Sood MD AkhilSoodMD ( View Tweet)
Open label study of only 8 weeks of steroid with tocilizumab for 1 year in GCA. 74% sustained steroid free remission at 1 year. Wow! Needs an RCT. Abstr#1413 #ACR21 @RheumNow https://t.co/c82qGJCFip
Richard Conway RichardPAConway ( View Tweet)
“NSAIDS are not off the table for older adults!” – Dr @unamakris says use⬇️dose &monitor; GFR may be misleading (toxicity seen w/normal Cr) She’s not a fan of tramadol, but recc topical pain meds, SSRI/NSRI, short-acting⬇️dose opioids when acet & nonpharm Rx fail @rheumnow #ACR21 https://t.co/rLeEagwrQU
TheDaoIndex KDAO2011 ( View Tweet)
KOA can not only ⬆️ morbidity, it also ⬆️s mortality - long term data from OAI - 5K pts, f/u 9 yrs . Greater KL scores (worse Xrays) - greater mortality!
#ACR21 abst#1028 @RheumNow https://t.co/jREmbEN2Ae
Bella Mehta bella_mehta ( View Tweet)
Exercise does not cause objective signs of increased disease activity in PsA
⭐️11 weeks of High Intensity Interval Training in PsA pts did not show worsening changes in MRI SI joint bone marrow edema.
Abs#1362
@RheumNow
#ACRBest
https://t.co/A3aOEy8Wz0 https://t.co/arPvjsbudm
Robert B Chao, MD doctorRBC ( View Tweet)
Clinical Pearl from Dr. @JKolfenbach
⭐️AAV doesn't typically cause hard palate lesions
Instead, consider:
➡️Cocaine-induced midline destructive lesion
➤try to send human neutrophil elastase ab (+ in cocaine use but not in AAV)
➡️Malignancy (NK T-cell lymphoma)
#ACR21 @RheumNow https://t.co/KIEXgCR23c
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
TNFi vs tofacitinib drug survival in RA
(based on two Canadian registries, PS adjusted)
This seems to be my refrain this ACR:
'TNF inhibitors: let's not forget, they're quite good'
#ACR21 ABST1217 @RheumNow @Janetbirdope https://t.co/MyFc6do0JL
David Liew drdavidliew ( View Tweet)
Dr Koster @MdWarrington @AliDuarteMD open label study baricitinib in relapsing GCA. Well-tolerated and allowed GC discontinuation by 24 weeks in most patients. Encouraging, we need an RCT! Abstr#1396 #ACR21 @RheumNow https://t.co/N2h54MHpIq
Richard Conway RichardPAConway ( View Tweet)
FDA update: Voclosporin Safety in #SLE RCTs #ACR21 https://t.co/xWCBELxQIc
Dr. John Cush RheumNow ( View Tweet)
FDA Safety Update - Dr. Nadia Habal reviewed approval of Voclosporin, anifrolumab, Avacopen and approved new indications for multiple drugs #ACR21 https://t.co/lAgQ4d0h2m
Dr. John Cush RheumNow ( View Tweet)
FDA safety update: OA Stakeholder Workshop June 2021 - Congrats to FDA & AFfor tackling this LARGE unmet need- difficulty in determining benefit in OA (pain, structure, biomarkers?) -more research needed #ACR21 https://t.co/hCWU8OL0Le
Dr. John Cush RheumNow ( View Tweet)
FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19:
1. RECOVERY - lower mortality
2. EMPACTA - Less progression to mech vent or death
3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej
Dr. John Cush RheumNow ( View Tweet)
FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH
Dr. John Cush RheumNow ( View Tweet)